DeflazacortCAS# 14484-47-0 |
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 14484-47-0 | SDF | Download SDF |
| PubChem ID | 189821 | Appearance | Powder |
| Formula | C25H31NO6 | M.Wt | 441.5 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | DMSO : ≥ 100 mg/mL (226.49 mM) *"≥" means soluble, but saturation unknown. | ||
| SMILES | CC1=NC2(C(O1)CC3C2(CC(C4C3CCC5=CC(=O)C=CC45C)O)C)C(=O)COC(=O)C | ||
| Standard InChIKey | FBHSPRKOSMHSIF-GRMWVWQJSA-N | ||
| Standard InChI | InChI=1S/C25H31NO6/c1-13-26-25(20(30)12-31-14(2)27)21(32-13)10-18-17-6-5-15-9-16(28)7-8-23(15,3)22(17)19(29)11-24(18,25)4/h7-9,17-19,21-22,29H,5-6,10-12H2,1-4H3/t17-,18-,19-,21+,22+,23-,24-,25+/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
Deflazacort Dilution Calculator
Deflazacort Molarity Calculator
| 1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
| 1 mM | 2.265 mL | 11.325 mL | 22.6501 mL | 45.3001 mL | 56.6251 mL |
| 5 mM | 0.453 mL | 2.265 mL | 4.53 mL | 9.06 mL | 11.325 mL |
| 10 mM | 0.2265 mL | 1.1325 mL | 2.265 mL | 4.53 mL | 5.6625 mL |
| 50 mM | 0.0453 mL | 0.2265 mL | 0.453 mL | 0.906 mL | 1.1325 mL |
| 100 mM | 0.0227 mL | 0.1133 mL | 0.2265 mL | 0.453 mL | 0.5663 mL |
| * Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. | |||||
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
Featured Products
- 5-(4-(2-(5-Ethylpyridin-2-yl)ethoxy)benzylidene)thiazolidine-2,4-dione
Catalog No.:BCC8720
CAS No.:144809-28-9
- L-703,664 succinate
Catalog No.:BCC7437
CAS No.:144776-01-2
- Brachynoside heptaacetate
Catalog No.:BCN6249
CAS No.:144765-80-0
- Clopidogrel Related Compound B
Catalog No.:BCN2688
CAS No.:144750-52-7
- Cyclo(Ala-Phe)
Catalog No.:BCN2411
CAS No.:14474-78-3
- Cyclo(Phe-Val)
Catalog No.:BCN2419
CAS No.:14474-71-6
- 2-4-Hydroxy-3-methoxyphenyl-7-methoxy-5-benzofuranpropanol
Catalog No.:BCN1564
CAS No.:144735-57-9
- 4F 4PP oxalate
Catalog No.:BCC6678
CAS No.:144734-36-1
- Telmisartan tert-butyl ester
Catalog No.:BCC9161
CAS No.:144702-26-1
- Telmisattan
Catalog No.:BCC3863
CAS No.:144701-48-4
- Fmoc-D-Cha-OH
Catalog No.:BCC3161
CAS No.:144701-25-7
- Hispidulin
Catalog No.:BCN6250
CAS No.:1447-88-7
New Products
- Alpiniaterpene A
Catalog No.:BCN7085
CAS No.:1448667-05-7
- Garjasmin
Catalog No.:BCN6251
CAS No.:144868-43-9
- Resiquimod (R-848)
Catalog No.:BCC4073
CAS No.:144875-48-9
- Junipediol B
Catalog No.:BCN6252
CAS No.:144881-19-6
- 4',9,9'-Trihydroxy-3'-methoxy-3,7'-epoxy-4,8'-oxyneolignan
Catalog No.:BCN1563
CAS No.:144881-21-0
- MRS 2693 trisodium salt
Catalog No.:BCC7386
CAS No.:1448858-83-0
- ML314
Catalog No.:BCC4154
CAS No.:1448895-09-7
- 1-Methyl-aminomethyl naphthalene
Catalog No.:BCC8471
CAS No.:14489-75-9
- 18alpha-Glycyrrhetinic acid
Catalog No.:BCC8328
CAS No.:1449-05-4
- 21-Episerratenediol
Catalog No.:BCN6253
CAS No.:1449-06-5
- 24-Methylenecycloartanone
Catalog No.:BCN7244
CAS No.:1449-08-7
- 24-Methylenecycloartan-3-ol
Catalog No.:BCN6254
CAS No.:1449-09-8
Deflazacort versus prednisone/prednisolone for maintaining motor function and delaying loss of ambulation: A post HOC analysis from the ACT DMD trial.[Pubmed:30028519]
Muscle Nerve. 2018 Nov;58(5):639-645.
INTRODUCTION: ACT DMD was a 48-week trial of ataluren for nonsense mutation Duchenne muscular dystrophy (nmDMD). Patients received corticosteroids for >/=6 months at entry and stable regimens throughout study. This post hoc analysis compares efficacy and safety for Deflazacort and prednisone/prednisolone in the placebo arm. METHODS: Patients received Deflazacort (n = 53) or prednisone/prednisolone (n = 61). Endpoints included change from baseline in 6-minute walk distance (6MWD), timed function tests, estimated age at loss of ambulation (extrapolated from 6MWD). RESULTS: Mean changes in 6MWD were -39.0 m (Deflazacort; 95% confidence limit [CL], -68.85, -9.17) and -70.6 m (prednisone/prednisolone; 95% CL, -97.16, -44.02). Mean changes in 4-stair climb were 3.79 s (Deflazacort; 95% CL, 1.54, 6.03) and 6.67 s (prednisone/prednisolone; 95% CL, 4.69, 8.64). CONCLUSIONS: This analysis, limited by its post hoc nature, suggests greater preservation of 6MWD and 4-stair climb with Deflazacort vs. prednisone/prednisolone. A head-to-head comparison will better define these differences. Muscle Nerve 58: 639-645, 2018.
Deflazacort is a glucocorticoid used as an anti-inflammatory and immunosuppressant.
Deflazacort,14484-47-0,Natural Products, buy Deflazacort , Deflazacort supplier , purchase Deflazacort , Deflazacort cost , Deflazacort manufacturer , order Deflazacort , high purity Deflazacort
